Background Dysuria following prostate rays therapy is a common toxicity that adversely affects patients quality of life and may be difficult to manage. for their localized prostate cancer with a median follow-up of 47?months. Bother associated with dysuria significantly increased from a baseline of 12% to a maximum of 43% at 1?month (p?